| Autor: |
Mato, Anthony R., Barrientos, Jacqueline C., Brander, Danielle M., Pagel, John M., Gutierrez, Meghan, Kadish, Karen, Tomlinson, Brian, Ghosh, Nilanjan, Giafis, Nick, Ipe, David, Upasani, Sandhya, Sundaram, Murali, Ferrante, Lucille, Amaya-Chanaga, Carlos, Iyengar, Reethi, Sharman, Jeff |
| Zdroj: |
Blood; November 2018, Vol. 132 Issue: 1, Number 1 Supplement 1 p4425-4425, 1p |
| Abstrakt: |
Background:Prior to the approvals of ibrutinib (ibr), idelalisib, and venetoclax, data from the Connect CLL registry showed that across 199 US centers only 65% of patients (pts) had FISH testing and 6% had IGHVtesting performed prior to the first chronic lymphocytic leukemia (CLL)-directed treatment (tx), and 40% had repeat FISH testing prior to a subsequent therapy (Mato, Br J Haematol2016). In today's era, molecular-genetic testing should be universally performed to guide tx decisions for pts with CLL, particularly for pts with 17p deletion (del[17p]), TP53mutation, and/or unmutated IGHV(U-CLL), as recommended by several guidelines. Whether the widespread availability of novel agents has improved prognostic testing patterns and if those results are appropriately utilized in selecting therapies remain important unanswered questions. InformCLL (NCT02582879) is a US, multicenter, prospective, observational real-world registry of pts with CLL receiving various lines of tx across 150 centers (96% community, 4% academic). This analysis describes rates of prognostic testing in pts with CLL stratified by line of therapy, proportions of pts with specific abnormalities, and current tx patterns in clinical practice in this registry. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
